ARS Pharmaceuticals, Inc (SPRY) Stock Forecast & Price Target
ARS Pharmaceuticals, Inc · NASDAQ
$5.75-0.20 (-3.28%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering ARS Pharmaceuticals, Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $24.00 to $40.00, a moderate spread. The average target of $31.33 sits 445% above the current $5.75. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to ARS Pharmaceuticals, Inc.
As of Jul, 3 of 3 firms rate SPRY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SPRY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.39 – $-0.12 · 3 analysts · -48% YoY
Next period, 3 analysts expect ARS Pharmaceuticals, Inc to earn $-0.27 a share (range $-0.39 – $-0.12), versus $-0.52 a year earlier. Full-year consensus is $-1.72, growing to $-0.94 the year after.
REVENUE · NEXT QUARTER
$49.9M
Range $41.9M – $55.7M · 3 analysts · +54% YoY
Revenue is expected to reach $49.9M (range $41.9M – $55.7M), +53.5% year-over-year. Full-year consensus is $139.8M, rising to $245.8M next year.
Top analysts covering ARS Pharmaceuticals, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SPRY.
#1
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$30.00+422.2% to target
Overall win rate
38%
+ Follow
#2
Roanna Ruiz
SVB Leerink
Buy
$24.00+317.8% to target
Coverage
—
+ Follow
#3
Ryan Deschner
Raymond James
Buy
No targeton SPRY
Coverage
—
+ Follow
#4
Joshua Schimmer
Cantor Fitzgerald
Buy
$25.00+335.2% to target
Coverage
—
+ Follow
#5
JW
Jason Wittes
Roth MKM
Buy
$40.00+596.3% to target
Coverage
—
+ Follow
SPRY stock forecast FAQ
What is SPRY's average 12-month price target?+
The 3 analysts with a live target average $31.33 for ARS Pharmaceuticals, Inc over the next 12 months, ranging from a $40.00 high to a $24.00 low.
Is SPRY stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SPRY?+
The Street-high target is $40.00 (Roth Capital), and the Street-low is $24.00 (Leerink Partners). The average of all 3 active targets is $31.33.
How many Wall Street analysts cover SPRY?+
3 analysts have an active rating on ARS Pharmaceuticals, Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering SPRY?+
Among analysts who currently cover SPRY, Josh Schimmer of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #140). Their current call is Buy with a $30.00 target.
What is ARS Pharmaceuticals, Inc's projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.39 – $-0.12) across 3 analysts. Full-year EPS is projected at $-1.72, rising to $-0.94 the following year.
How much revenue is ARS Pharmaceuticals, Inc expected to report next quarter?+
Consensus revenue is $49.9M (range $41.9M – $55.7M). Full-year revenue is projected at $139.8M, growing to $245.8M next year.
Have analysts been upgrading or downgrading SPRY lately?+
As of Jul, 3 of 3 firms rate SPRY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SPRY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
